NOVN.SW stock CHF 108.50 on 06 Jan 2026 intraday: Most active on SIX, catalysts ahead
NOVN.SW stock is trading at CHF 108.50 intraday on 06 Jan 2026 and ranks among the SIX’s most active names by volume. We see a modest intraday pullback of -1.00% with 3,220,892 shares traded versus an average of 2,844,784. The move tracks broad healthcare action but also reacts to firm valuation and upcoming catalysts, including an earnings release scheduled for 04 Feb 2026. Below we break down price action, valuation, technicals, and model forecasts to show what active traders and longer-term investors should watch today.
NOVN.SW stock: Intraday price and liquidity
Novartis AG (NOVN.SW) is trading between the day low CHF 107.68 and day high CHF 109.82 on SIX in Switzerland. Volume of 3,220,892 shares gives a relative volume of 1.13, confirming the stock’s most active status this session. The stock opened at CHF 109.82 after a previous close of CHF 109.60, and intraday weakness is small compared with a year high of CHF 110.88 and a year low of CHF 81.10.
NOVN.SW stock: Fundamentals and valuation
Novartis carries a market cap near CHF 208.19 billion and trades at a trailing PE of 18.84 on EPS CHF 5.76. The dividend yield stands at 3.19% with a payout ratio of 54.32%. Return on equity is strong at 34.12%, while the current ratio is 0.88, reflecting working-capital intensity in pharmaceuticals. Price-to-book is 6.13 and price-to-sales is 4.70, below some large peers on growth-adjusted metrics but above the sector average PE of 32.55, which highlights relative valuation versus healthcare peers.
NOVN.SW stock: Technicals and trading setup
Short-term momentum is neutral to constructive: RSI is 58.45, MACD is 1.31 with a signal of 1.18, and the stock sits near the Bollinger middle band (CHF 107.40). The 50-day average is CHF 105.20 and the 200-day average is CHF 98.82, so trend bias remains upward on moving-average spacing. Key intraday support is CHF 107.68 and resistance near CHF 110.40 (upper BB). Traders may use a tight stop below CHF 107.00 for short-term longs.
NOVN.SW stock: News, catalysts and calendar
The next major calendar item is the FY2025 earnings release and call on 04 Feb 2026. Recent analyst estimate pages and consensus trackers updated in the last 24 hours highlight EPS and revenue revisions heading into that event. For context on analyst views and updated estimates see Yahoo Finance analyst pages source and the Novartis quote summary source. Business drivers include performance in Innovative Medicines, the Sandoz generics unit, and progress on key collaborations such as inclisiran.
Meyka AI rates NOVN.SW with a score out of 100 and Meyka AI’s forecast model projects
Meyka AI rates NOVN.SW with a score out of 100: 81.63 — Grade A — Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a short-term monthly figure of CHF 113.03, a quarterly forecast of CHF 101.29, and a 12-month projection of CHF 100.53. Versus the current price CHF 108.50, these imply a monthly upside of +4.18%, a quarterly downside of -6.65%, and a 12-month downside of -7.35%. Forecasts are model-based projections and not guarantees.
NOVN.SW stock: Price targets, risks and sector context
We outline realistic price targets for active traders and investors: a conservative target CHF 100.00, a base case CHF 115.00, and a bull case CHF 140.00, reflecting product approvals and successful Sandoz restructuring. Key risks include generic pressure, regulatory setbacks, and FX headwinds. On a sector basis, Novartis’s PE of 18.84 sits below the Swiss healthcare average PE of 32.55, which may attract value-focused investors while growth-focused funds prefer higher multiple peers.
Final Thoughts
NOVN.SW stock is the Swiss healthcare market’s most active security this intraday session, trading at CHF 108.50 on 06 Jan 2026 with above-average liquidity. Fundamentals remain solid: PE 18.84, EPS CHF 5.76, dividend yield 3.19%, and ROE 34.12% support a constructive long-term view. Technicals show momentum but limited upside near the year high; short-term traders should watch CHF 107.00 support and the CHF 110.40 resistance band. Meyka AI’s model projects a near-term monthly figure of CHF 113.03 (implied upside +4.18%) but flags a flatter 12-month model outcome near CHF 100.53. Active investors should balance Novartis’s attractive cash flow and dividend profile against generic and regulatory risks. We recommend watching the 04 Feb 2026 earnings release and using the outlined conservative, base, and bull price bands to size positions. Meyka AI is the AI-powered market analysis platform providing this model view; forecasts are not guarantees and investors should conduct their own research.
FAQs
NOVN.SW stock is trading at **CHF 108.50** intraday (06 Jan 2026) with volume **3,220,892**, above the average **2,844,784**, confirming heavy activity on the SIX trading session.
Novartis trades at a trailing PE of **18.84**, below the healthcare sector average PE of **32.55**. That gap suggests relative value but requires consideration of growth, pipeline and Sandoz margin dynamics.
Meyka AI’s forecast model projects **CHF 113.03** for the next month, implying a **+4.18%** upside versus **CHF 108.50**. Forecasts are model-based projections and not guarantees.
Key risks for NOVN.SW stock include generic competition, regulatory or trial setbacks, FX fluctuations, and Sandoz execution. Any negative surprise in the 04 Feb 2026 results could pressure the stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
